Clinical research, Pharmacology, ClinicalTrials.gov, Health care, Clinical trial, Informed consent
Alzheimer’s Drug Developer Alzheon Secures $50 Million
The Framingham, Mass.-based biotech company is testing the drug in late-stage, Phase 3 clinical trials.
Alzheimer’s Drug Developer Alzheon Secures $50 Million
The Framingham, Mass.-based biotech company is testing the drug in late-stage, Phase 3 clinical trials.
We are sorry, we could not find the related article
Subscribe to Biotech - Startups
UPDATED: European drug regulator votes down Biogen's controversial Alzheimer's drug
Following an oral explanation held at the November meeting of the EMA's human medicines committee, Biogen received
Promising drug for Huntington disease fails in major trial
Roche suddenly halts study of antisense treatment designed to slow or stop fatal disease
Biotech’s Year-End To-Do List
The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.
Aducanumab for Alzheimer’s disease?
Patients and families need hope, not false hope The US licensing of Biogen’s aducanumab as “the first ever disease modifying drug for Alzheimer’s disease” was hailed as a major advance by ...
FDA Approval of a New Alzheimer’s Drug Comes With Controversy
Aducanumab is the first approved drug that targets a possible underlying cause of Alzheimer's disease
Biogen, fresh off coveted FDA nod for Aduhelm, must now navigate ethics minefield for phase 4 trial
After the Aduhelm approval set a precedent for FDA clearance based on surrogate endpoints, all eyes will be on Biogen as it conducts a trial in the post-approval environment. The biotech, ...
Oxford- and Porto-based iLoF secures €870K to create an AI-powered digital library of disease biomarkers and help find Alzheimer’s cure
iLoF (Intelligent Lab on Fiber), a startup which is working on a patented cloud-based library of 'disease fingerprints', just secured €870K of additional funding from Microsoft's venture ...
A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Here’s what you need to know about aducanumab, the controversy around it, and the issues that will take center stage at the FDA meeting.
NIH Begins Clinical Trial of Hydroxychloroquine and Azithromycin to Treat COVID-19
A clinical trial has begun to evaluate whether the malaria drug hydroxychloroquine, given together with the antibiotic azithromycin, can prevent hospitalization and death from coronavirus ...
GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS
CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. ...
How AI can speed up clinical trials
The average clinical trial process takes years to complete, costs hundreds of millions — if not billions— of dollars, and only 14 percent of drugs that enter clinical trials will get ...
Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Minority groups could have a harder time accessing Biogen Inc.’s Alzheimer’s drug under Medicare’s preliminary decision to limit coverage to patients enrolled in clinical trials, policy ...
FDA, NIH's newest app asks clinicians to log case data when treating difficult infections
The CURE ID online data repository's crowdsourcing approach could help the agency to identify novel uses for approved drugs.
Medicare Plans to Restrict Coverage of New Alzheimer's Drug
Proposal would cover aducanumab (Aduhelm) in patients on qualifying clinical trials
COVID-19 therapies will be needed by fall
It’s all hands on deck as government agencies, researchers, startups, biopharma giants, health care workers and payers combine their resources to develop proven COVID-19 therapies that can ...